Web8 mrt. 2024 · Voyager Therapeutics Inc.'s VYGR, +6.22% stock gained 16.8% in premarket trading on Tuesday after the gene therapy company said it inked a deal with Novartis [n: nvs] worth up to $1.7 billion. Novartis will pay $54 million upfront to license Voyager's novel adeno-associated virus (AAV) capsids for use with the gene therapies it's developing. WebVYGR - Voyager Therapeutics, Inc. - SEC Form 4 Insider Trading Screener. Manufactured Goods - Chemicals - Biological Products, (No Diagnostic Substances) - VYGR ( 1640266) 36 results. Finviz - SEC - Yahoo - Stockcharts - Tradingview.
VYGR Voyager Therapeutics, Inc. - SeekingAlpha
Web12 apr. 2024 · Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) top owners are individual investors with 29% stake, while 23% is held by institutions finance.yahoo.com - March 12 … Web11 apr. 2024 · VYGR: Voyager Therapeutics - Price & Consenus Chart - Zacks.com Voyager Therapeutics (VYGR) (Delayed Data from NSDQ) $7.98 USD -0.05 (-0.62%) Updated Apr 11, 2024 04:00 PM ET After-Market:... deichmann safety boots
Voyager Therapeutics Inc., VYGR Advanced Chart - (NAS
Web8 apr. 2024 · VYGR’s current price about 3.52% and 2.01% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 54.73, while 7-day volatility ratio is 5.52% and 6.00% in the 30-day chart. Further, Voyager Therapeutics Inc. (VYGR) has a beta value of 1.13, and an average true range (ATR) of … Web1 dag geleden · Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500. Click here - the VYGR analysis is free » About 12 Month EPS WebVoyager Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View VYGR financial statements in full. fenerbahce players 2018